Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience

References

• Ferrari AJ, Abrey LE, Blay J-Y, . Summary statement on primary central nervous system lymphomas form the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003;21:2407–2414.
   PubMed Web of Science ®Google Scholar
• Benjamin WC, Marcus SM, Topham A, . Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 1997;79:2409–2413.
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859–863.
   PubMed Web of Science ®Google Scholar
• Ferrari AJM, Blay J-Y, Reni M, . Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group Experience. J Clin Oncol 2003;21:266–272.
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Ogino H, Hasegawa M, . Results of radiation monotherapy for primary central nervous lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 2005;62:809–813.
   PubMed Web of Science ®Google Scholar
• Mead GM, Bleehen NM, Gregor A, . A medical research council randomized trail in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy. Cancer 2000;89:1359–1370.
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, . High dose methotrexate-based chemotherapy followed by consolidation radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II trial 20962. J Clin Oncol 2003;21:4483–4488.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144–3150.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, . Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643–4648.
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O'Neill A, . Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044–1049.
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Taillandier L, Chinot O, . Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003;21:2726–2731.
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A, . Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489–4495.
   PubMed Web of Science ®Google Scholar
• Juergens A, Pels H, Rogowski S, . Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010;67:182–189.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, . High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11:1036–1047.
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K, . Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742–749.
   PubMed Web of Science ®Google Scholar
• Cheng T, Forsyth P, Chaudhry A, . High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003;31:679–685.
   PubMed Web of Science ®Google Scholar
• Campen CJ, Tombleson RL, Green MR. High dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma. J Neurooncol 2011;101: 345–355.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Ihorst G, . High dose chemotherapy with autologous stem cell transplantation and hyperfractioned radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865–7380.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Muller F, Feuerhake F, . High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008;93:147–148.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJM, . Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–5043.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kluin PM, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Swerlow SH, Campo E, Harris NL, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2008. pp 240–241.
   Google Scholar
• Abrey L, Moskowitz CH, Mason WP, . Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent to treat analysis. J Clin Oncol 2003;21:4151–4156.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Lee DH, Choi DR, . Feasibility of BU, CY, and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-centre experience. Bone Marrow Transplant 2011;46:105–109.
   PubMed Web of Science ®Google Scholar
• Motl S, Zhuang Y, Waters CM, . Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 2006;45:871–903.
   PubMed Web of Science ®Google Scholar
• Wiebe VJ, Smith BR, DeGregorio MW, . Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 1992;13:241–270.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Reni M, Foppoli M, . High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009;374:1512–1520.
   PubMed Web of Science ®Google Scholar